{"success":true,"data":{"pressRelease":{"id":"60769","rtpr_id":"nGNX4cpQhf","ticker":"HUMA","exchange":"NASDAQ","all_tickers":["HUMA"],"title":"Humacyte, Inc. Announces Proposed Public Offering of Common Stock","author":"Globe Newswire","published_at":"2026-06-11T00:56:21.526Z","article_body":"DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA),\na commercial-stage biotechnology platform company developing universally\nimplantable, bioengineered human tissues at commercial scale, today announced\nthat it has commenced an underwritten public offering of its common stock. In\naddition, Humacyte intends to grant the underwriters an option for a period of\n30 days to purchase up to an additional 15% of the number of shares of common\nstock sold in connection with the offering. All of the shares of common stock\nare being offered by Humacyte.\n\nBarclays, BTIG and Titan Partners, a division of American Capital Partners,\nare acting as joint book-running managers for the offering. The offering is\nsubject to market conditions and there can be no assurance as to whether or\nwhen the offering may be completed, or as to the actual size or terms of the\noffering.\n\nHumacyte intends to use the net proceeds that it will receive from the\noffering to fund the commercialization of Symvess(®), the planned filing of a\nBiologics License Application supplement in a hemodialysis indication and\nrelated activities, the development of the product candidates in its pipeline\nand for working capital and general corporate purposes.\n\nA shelf registration statement on Form S-3 (No. 333-290231) was previously\nfiled with the Securities and Exchange Commission (the “SEC”) on September\n12, 2025 and declared effective by the SEC on September 22, 2025. The\nsecurities will be offered by means of a prospectus supplement and\naccompanying prospectus relating to the offering that form a part of the\nregistration statement. A preliminary prospectus supplement and the\naccompanying prospectus relating to and describing the terms of the offering\nwill be filed with the SEC and will be available on the SEC’s website at\nwww.sec.gov. Copies of the preliminary prospectus supplement, when available,\nand the accompanying prospectus relating to the offering may be obtained from\nBarclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island\nAvenue, Edgewood, New York 11717, by telephone at (888) 603-5847, or by email\nat barclaysprospectus@broadridge.com; BTIG, LLC, 65 East 55th Street, New\nYork, New York 10022, by telephone at (212) 593-7555 or by email at\nProspectusDelivery@btig.com; or Titan Partners Group LLC, a division of\nAmerican Capital Partners, LLC, 4 World Trade Center, 49th Floor, New York, NY\n10007, by phone at (929) 833-1246 or by email at\nprospectus@titanpartnersgrp.com.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy any of the securities described herein, nor shall there be\nany sale of these securities in any state or jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to registration or qualification\nunder the securities laws of any such state or jurisdiction.\n\nAbout Humacyte\n\nHumacyte, Inc. (Nasdaq: HUMA) is a commercial-stage biotechnology platform\ncompany developing universally implantable, bioengineered human tissues at\ncommercial scale, and in the first quarter of 2025 commenced the United States\ncommercial launch of Symvess, its first FDA-approved product. Humacyte is\npioneering the development and manufacture of off-the-shelf, universally\nimplantable, bioengineered human tissues, advanced tissue constructs and organ\nsystems with the goal of improving the lives of patients and transforming the\npractice of medicine. Humacyte is leveraging its novel, scalable technology\nplatform to develop proprietary, bioengineered, acellular human tissues for\nuse in the treatment of diseases and conditions across a range of anatomic\nlocations in multiple therapeutic areas.\n\nFor uses other than the U.S. Food and Drug Administration (“FDA”) approval\nin the extremity vascular trauma indication, the acellular tissue engineered\nvessel (“ATEV”) is an investigational product and has not been approved\nfor sale by the FDA or any other regulatory agency.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements that are based on\nbeliefs and assumptions and on information currently available. In some cases,\nyou can identify forward-looking statements by the following words: “may,”\n“will,” “could,” “would,” “should,” “expect,”\n“intend,” “plan,” “anticipate,” “believe,” “estimate,”\n“predict,” “project,” “potential,” “continue,” “ongoing”\nor the negative of these terms or other comparable terminology, although not\nall forward-looking statements contain these words. These statements involve\nrisks, uncertainties, and other factors that may cause actual results, levels\nof activity, performance, or achievements to be materially different from the\ninformation expressed or implied by these forward-looking statements. Although\nHumacyte believes that it has a reasonable basis for each forward-looking\nstatement contained in this press release, Humacyte cautions you that these\nstatements are based on a combination of facts and factors currently known by\nit and its projections of the future, about which Humacyte cannot be certain.\nForward-looking statements in this press release include, but are not limited\nto, statements regarding the timing and success of the proposed offering;\nwhether Humacyte will be able to raise capital through the sale of shares of\ncommon stock in the offering and the anticipated use of proceeds from the\nproposed offering. Humacyte cannot assure you that the forward-looking\nstatements in this press release will prove to be accurate. These\nforward-looking statements are subject to a number of significant risks and\nuncertainties that could cause actual results to differ materially from\nexpected results, including, among others, changes in applicable laws or\nregulations, the possibility that Humacyte may be adversely affected by other\neconomic, business, and/or competitive factors, and other risks and\nuncertainties, including those described under the header “Risk Factors”\nin Humacyte’s Annual Report on Form 10-K for the year ended December 31,\n2025 and in Humacyte’s Quarterly Report on Form 10-Q for the quarter ended\nMarch 31, 2026, each filed by Humacyte with the SEC, and in future SEC\nfilings. Most of these factors are outside of Humacyte’s control and are\ndifficult to predict. Furthermore, if the forward-looking statements prove to\nbe inaccurate, the inaccuracy may be material. In light of the significant\nuncertainties in these forward-looking statements, you should not regard these\nstatements as a representation or warranty by Humacyte or any other person\nthat Humacyte will achieve its objectives and plans in any specified time\nframe, or at all. Except as required by law, Humacyte has no current intention\nof updating any of the forward-looking statements in this press release. You\nshould, therefore, not rely on these forward-looking statements as\nrepresenting Humacyte’s views as of any date subsequent to the date of this\npress release.\n\nHumacyte Investor Contact:\nJoyce Allaire\nLifeSci Advisors LLC\n+1-617-435-6602\njallaire@lifesciadvisors.com\ninvestors@humacyte.com\n\nHumacyte Media Contact:\nRich Luchette\nPrecision Strategies\n+1-202-845-3924\nrich@precisionstrategies.com\nmedia@humacyte.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e81aff26-ead8-404d-aebb-159b45c3e7b1)\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX4cpQhf","title":"Humacyte, Inc. Announces Proposed Public Offering of Common Stock","author":"Globe Newswire","ticker":"HUMA","created":"2026-06-11T00:56:21.526Z","tickers":["HUMA"],"exchange":"NASDAQ","article_body":"DURHAM, N.C., June 10, 2026 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA),\na commercial-stage biotechnology platform company developing universally\nimplantable, bioengineered human tissues at commercial scale, today announced\nthat it has commenced an underwritten public offering of its common stock. In\naddition, Humacyte intends to grant the underwriters an option for a period of\n30 days to purchase up to an additional 15% of the number of shares of common\nstock sold in connection with the offering. All of the shares of common stock\nare being offered by Humacyte.\n\nBarclays, BTIG and Titan Partners, a division of American Capital Partners,\nare acting as joint book-running managers for the offering. The offering is\nsubject to market conditions and there can be no assurance as to whether or\nwhen the offering may be completed, or as to the actual size or terms of the\noffering.\n\nHumacyte intends to use the net proceeds that it will receive from the\noffering to fund the commercialization of Symvess(®), the planned filing of a\nBiologics License Application supplement in a hemodialysis indication and\nrelated activities, the development of the product candidates in its pipeline\nand for working capital and general corporate purposes.\n\nA shelf registration statement on Form S-3 (No. 333-290231) was previously\nfiled with the Securities and Exchange Commission (the “SEC”) on September\n12, 2025 and declared effective by the SEC on September 22, 2025. The\nsecurities will be offered by means of a prospectus supplement and\naccompanying prospectus relating to the offering that form a part of the\nregistration statement. A preliminary prospectus supplement and the\naccompanying prospectus relating to and describing the terms of the offering\nwill be filed with the SEC and will be available on the SEC’s website at\nwww.sec.gov. Copies of the preliminary prospectus supplement, when available,\nand the accompanying prospectus relating to the offering may be obtained from\nBarclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island\nAvenue, Edgewood, New York 11717, by telephone at (888) 603-5847, or by email\nat barclaysprospectus@broadridge.com; BTIG, LLC, 65 East 55th Street, New\nYork, New York 10022, by telephone at (212) 593-7555 or by email at\nProspectusDelivery@btig.com; or Titan Partners Group LLC, a division of\nAmerican Capital Partners, LLC, 4 World Trade Center, 49th Floor, New York, NY\n10007, by phone at (929) 833-1246 or by email at\nprospectus@titanpartnersgrp.com.\n\nThis press release shall not constitute an offer to sell or the solicitation\nof an offer to buy any of the securities described herein, nor shall there be\nany sale of these securities in any state or jurisdiction in which such offer,\nsolicitation or sale would be unlawful prior to registration or qualification\nunder the securities laws of any such state or jurisdiction.\n\nAbout Humacyte\n\nHumacyte, Inc. (Nasdaq: HUMA) is a commercial-stage biotechnology platform\ncompany developing universally implantable, bioengineered human tissues at\ncommercial scale, and in the first quarter of 2025 commenced the United States\ncommercial launch of Symvess, its first FDA-approved product. Humacyte is\npioneering the development and manufacture of off-the-shelf, universally\nimplantable, bioengineered human tissues, advanced tissue constructs and organ\nsystems with the goal of improving the lives of patients and transforming the\npractice of medicine. Humacyte is leveraging its novel, scalable technology\nplatform to develop proprietary, bioengineered, acellular human tissues for\nuse in the treatment of diseases and conditions across a range of anatomic\nlocations in multiple therapeutic areas.\n\nFor uses other than the U.S. Food and Drug Administration (“FDA”) approval\nin the extremity vascular trauma indication, the acellular tissue engineered\nvessel (“ATEV”) is an investigational product and has not been approved\nfor sale by the FDA or any other regulatory agency.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements that are based on\nbeliefs and assumptions and on information currently available. In some cases,\nyou can identify forward-looking statements by the following words: “may,”\n“will,” “could,” “would,” “should,” “expect,”\n“intend,” “plan,” “anticipate,” “believe,” “estimate,”\n“predict,” “project,” “potential,” “continue,” “ongoing”\nor the negative of these terms or other comparable terminology, although not\nall forward-looking statements contain these words. These statements involve\nrisks, uncertainties, and other factors that may cause actual results, levels\nof activity, performance, or achievements to be materially different from the\ninformation expressed or implied by these forward-looking statements. Although\nHumacyte believes that it has a reasonable basis for each forward-looking\nstatement contained in this press release, Humacyte cautions you that these\nstatements are based on a combination of facts and factors currently known by\nit and its projections of the future, about which Humacyte cannot be certain.\nForward-looking statements in this press release include, but are not limited\nto, statements regarding the timing and success of the proposed offering;\nwhether Humacyte will be able to raise capital through the sale of shares of\ncommon stock in the offering and the anticipated use of proceeds from the\nproposed offering. Humacyte cannot assure you that the forward-looking\nstatements in this press release will prove to be accurate. These\nforward-looking statements are subject to a number of significant risks and\nuncertainties that could cause actual results to differ materially from\nexpected results, including, among others, changes in applicable laws or\nregulations, the possibility that Humacyte may be adversely affected by other\neconomic, business, and/or competitive factors, and other risks and\nuncertainties, including those described under the header “Risk Factors”\nin Humacyte’s Annual Report on Form 10-K for the year ended December 31,\n2025 and in Humacyte’s Quarterly Report on Form 10-Q for the quarter ended\nMarch 31, 2026, each filed by Humacyte with the SEC, and in future SEC\nfilings. Most of these factors are outside of Humacyte’s control and are\ndifficult to predict. Furthermore, if the forward-looking statements prove to\nbe inaccurate, the inaccuracy may be material. In light of the significant\nuncertainties in these forward-looking statements, you should not regard these\nstatements as a representation or warranty by Humacyte or any other person\nthat Humacyte will achieve its objectives and plans in any specified time\nframe, or at all. Except as required by law, Humacyte has no current intention\nof updating any of the forward-looking statements in this press release. You\nshould, therefore, not rely on these forward-looking statements as\nrepresenting Humacyte’s views as of any date subsequent to the date of this\npress release.\n\nHumacyte Investor Contact:\nJoyce Allaire\nLifeSci Advisors LLC\n+1-617-435-6602\njallaire@lifesciadvisors.com\ninvestors@humacyte.com\n\nHumacyte Media Contact:\nRich Luchette\nPrecision Strategies\n+1-202-845-3924\nrich@precisionstrategies.com\nmedia@humacyte.com\n\n(https://www.globenewswire.com/NewsRoom/AttachmentNg/e81aff26-ead8-404d-aebb-159b45c3e7b1)\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-06-11T00:56:21.574276575Z","server_sent_at_ms":1781139381574},"received_at":"2026-06-11T00:56:21.645Z","source_url":"https://www.globenewswire.com/news-release/2026/06/10/3310085/0/en/Humacyte-Inc-Announces-Proposed-Public-Offering-of-Common-Stock.html"},"analysis":{"id":"50194","press_release_id":"60769","analysis_json":{"industry":{"label":"Biotechnology","sector":"Health Care"},"redFlags":["Public offering signals need for liquidity and results in shareholder dilution","Offering size and price not yet determined, subject to market conditions"],"eventType":"offering","narrative":"Humacyte has commenced an underwritten public offering of its common stock to fund the commercialization of its FDA-approved product Symvess and support pipeline development.\n\nBarclays, BTIG, and Titan Partners are acting as joint book-running managers for the offering, which is subject to market conditions.\n\nThe company intends to use the net proceeds for working capital and general corporate purposes, in addition to specific commercial and regulatory activities.","sentiment":"bearish","agentHooks":{"shouldPost":true,"suggestedAngle":"HUMA raises capital via public offering to fund Symvess commercialization; watch for dilution impact once pricing is announced."},"keyFigures":{"customDimensions":{"overallotment_option":"15%"}},"quotedText":"Humacyte intends to use the net proceeds that it will receive from the offering to fund the commercialization of Symvess(®), the planned filing of a Biologics License Application supplement in a hemodialysis indication and related activities, the development of the product candidates in its pipeline and for working capital and general corporate purposes.","namedEntities":{"people":[{"name":"Joyce Allaire","role":"Investor Contact"},{"name":"Rich Luchette","role":"Media Contact"}],"products":["Symvess"],"companies":[{"name":"Humacyte, Inc.","ticker":"HUMA","relationship":"filer"},{"name":"Barclays","relationship":"underwriter"},{"name":"BTIG","relationship":"underwriter"},{"name":"Titan Partners","relationship":"underwriter"},{"name":"American Capital Partners","relationship":"parent of underwriter"},{"name":"Securities and Exchange Commission","relationship":"regulator"}],"dollarAmounts":[]},"materialImpact":{"score":3,"reasoning":"The company is commencing an underwritten public offering to fund commercialization and working capital. While the use of proceeds supports growth (Symvess commercialization), the act of raising equity capital signals a need for liquidity and results in immediate dilution. The lack of a stated price or size prevents a definitive assessment of the discount, but the event itself is a standard dilutive financing signal."},"tickerRelevance":{"others":[],"primary":"HUMA"},"globalImportance":25,"audienceRelevance":30,"eventTypeSecondary":["dilution"],"importanceComponents":{"tickerTier":"small-cap","eventGravity":"moderate","sectorWeight":"high","householdBrandBoost":"low","marketCapAdjustment":"neutral","retailFavoriteBoost":"low"}},"event_type":"offering","event_type_secondary":["dilution"],"sentiment":"bearish","material_impact_score":3,"narrative":"Humacyte has commenced an underwritten public offering of its common stock to fund the commercialization of its FDA-approved product Symvess and support pipeline development.\n\nBarclays, BTIG, and Titan Partners are acting as joint book-running managers for the offering, which is subject to market conditions.\n\nThe company intends to use the net proceeds for working capital and general corporate purposes, in addition to specific commercial and regulatory activities.","key_figures":{"customDimensions":{"overallotment_option":"15%"}},"named_entities":{"people":[{"name":"Joyce Allaire","role":"Investor Contact"},{"name":"Rich Luchette","role":"Media Contact"}],"products":["Symvess"],"companies":[{"name":"Humacyte, Inc.","ticker":"HUMA","relationship":"filer"},{"name":"Barclays","relationship":"underwriter"},{"name":"BTIG","relationship":"underwriter"},{"name":"Titan Partners","relationship":"underwriter"},{"name":"American Capital Partners","relationship":"parent of underwriter"},{"name":"Securities and Exchange Commission","relationship":"regulator"}],"dollarAmounts":[]},"model_name":"qwen3_6_27b_awq","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-06-11T00:57:20.807Z","global_importance":25,"audience_relevance":30,"importance_components":{"tickerTier":"small-cap","eventGravity":"moderate","sectorWeight":"high","householdBrandBoost":"low","marketCapAdjustment":"neutral","retailFavoriteBoost":"low"}},"durationMs":59155,"modelName":"george-droid-qwen-72b"}}